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Background: Recombinant proteins are routinely overexpressed in metabolic engineering. It is well known that
some over-expressed heterologous recombinant enzymes are insoluble with little or no enzymatic activity. This
study examined the solubility of over-expressed homologous enzymes of the deoxyxylulose phosphate pathway
(DXP) and the impact of inclusion body formation on metabolic engineering of microbes.
Results: Four enzymes of this pathway (DXS, ISPG, ISPH and ISPA), but not all, were highly insoluble, regardless of
the expression systems used. Insoluble dxs (the committed enzyme of DXP pathway) was found to be inactive.
Expressions of fusion tags did not significantly improve the solubility of dxs. However, hypertonic media containing
sorbitol, an osmolyte, successfully doubled the solubility of dxs, with the concomitant improvement in microbial
production of the metabolite, DXP. Similarly, sorbitol significantly improved the production of soluble and
functional ERG12, the committed enzyme in the mevalonate pathway.
Conclusion: This study demonstrated the unanticipated findings that some over-expressed homologous enzymes
of the DXP pathway were highly insoluble, forming inclusion bodies, which affected metabolite formation. Sorbitol
was found to increase both the solubility and function of some of these over-expressed enzymes, a strategy to
increase the production of secondary metabolites.
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Metabolic engineeringIntroduction
Isoprenoids, a large family of natural compounds includ-
ing many plant based pharmaceuticals such as artemisinin
[1] and paclitaxel [2], are produced by the deoxyxylulose
phosphate (DXP) pathway and/or the mevalonate (MVA)
pathway in nature [3]. The current industrial isoprenoid
production methods include direct extraction from plants
and semi-synthesis using plant metabolites [4]. These pro-
cesses are all restricted by the supply of specific plant
materials, which are often affected by unpredictable factors
including variations in weather and market fluctuations [5].* Correspondence: heng-phon_too@nuhs.edu.sg
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reproduction in any medium, provided the orTo improve sustainability and production capacity of iso-
prenoids, heterologous biosynthesis from economical car-
bon sources in microbes has been intensively studied in
the past decade [2,5]. To date, there have been many suc-
cessful reports of using the DXP pathway to produce iso-
prenoid nutraceuticals (e.g. lycopene [6-10] and other
carotenoids [11,12]) and pharmaceuticals (e.g. artemisinin
precursors [13,14] and paclitaxel precursors [2]).
To increase carbon flux through the DXP pathway, the
enzymes involved were overexpressed [2,6-14] to catalyze
the bio-transformations of the DXP metabolites in vivo.
So far, four enzymes (DXS, IDI, ISPD and ISPF) have been
identified to be rate limiting based on a series of empirical
studies [9,15]. The expression levels of these four enzymes
have also been semi-empirically optimized for paclitaxel
precursor production [2]. It is well accepted that some re-
combinant proteins can form insoluble aggregates (termed
as inclusion bodies), generally regarded to be functionallytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Metabolites and enzymes related to the DXP pathway.
GAP: glyceraldehyde-3-phosphate; PYR: pyruvate; DXP: 1-deoxy-D-
xylulose 5-phosphate; MEP: 2C-methyl-D-erythritol 4-phosphate;
CDP-ME: 4-diphosphocytidyl-2C-methyl D-erythritol; CDP-MEP: 4-
diphosphocytidyl-2C-methyl D-erythritol 2-phosphate; MEC: 2C-
methyl-D-erythritol 2,4-diphosphate; HMBPP: (E)-4-hydroxy-3-methyl-
but-2-enyl pyrophosphate; IPP: Isopentenyl diphosphate; DMAPP:
Dimethylallyl diphosphate; FPP: Farnesyl diphosphate; DXS: 1-deoxy-
D-xylulose 5-phosphate synthase; DXR: 1-deoxy-D-xylulose 5-
phosphate reductase; ISPD: 4-diphosphocytidyl-2C-methyl-D-
erythritol synthase; ISPE: 4-diphosphocytidyl-2-C-methylerythritol
kinase; ISPF: 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase;
ISPG: 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase; ISPH:
1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate reductase; IDI:
isopentenyl diphosphate isomerase; ispA: farnesyl diphosphate
synthase.
Table 1 Solubility of the enzymes in the DXP pathway
predicted in silico and determined in vitro
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expressed recombinant endogenous DXP enzymes form-
ing inclusion bodies and their impacts on the flux through
the pathway have yet to be systematically investigated.
This study examined the solubility status of all the DXP
enzymes when overexpressed and attempted to demon-
strate the importance of protein solubility in the produc-
tion of secondary metabolites. Computational prediction
was initially explored to evaluate the solubility status and
empirical verifications were carried out in E. coli. An un-
anticipated and critical observation is that many DXP
enzymes (DXS, ISPA, ISPG and ISPH) were found to be
highly insoluble. Interestingly, the enzymes IDI, ISPD and
ISPF, thought to be rate-limiting and hence useful for the
enhancement of isoprenoids production [9], were found
to be highly soluble. From these observations, it is now
necessary to reevaluate the use of the other highly insol-
uble DXP enzymes for enhancing isoprenoid production.
Attempts were also made to optimize the solubility of the
insoluble enzymes and to examine the enhancements in
isoprenoid production.
Results
Solubility of over-expressed recombinant DXP
pathway enzymes
DXP pathway has so far been characterized to be a linear
pathway [3], producing isopentenyl diphosphate (IPP) and
dimethylallyl diphosphate (DMAPP) from pyruvate and
glyceraldehyde 3-phosphate (GAP), two important meta-
bolites in central metabolism (Figure 1). IPP and DMAPP
(C5) are further assembled into geranyl diphosphate (GPP,
C10) and farnesyl diphosphate (FPP, C15), precursors for
all C10 and C15 isoprenoids [4]. To date, little is known
of the solubility of the enzymes involved in this pathway
when overexpressed for the production of isoprenoids.
As a first attempt, the solubility of the enzymes in the
DXP pathway was evaluated by in silico modeling. Several
correlation algorithms built on published experimental
data have been reported [17-21]. Revised WH method
[18], one of the most commonly used and accurate meth-
ods [21], was used to predict solubility of the DXP path-
way enzymes. Some of the enzymes (DXS, ISPE and
ISPG) were predicted by these methods to be insoluble
when overexpressed in E. coli (Table 1). Similarly, in vitro
expression study [22] showed that a subgroup of the DXP
pathway proteins (DXS and IDI) were insoluble (Table 1).
As in silico prediction did not completely agree with the
published in vitro expression data, it was essential to de-
termine the solubility of the enzymes when overexpressed
in vivo.
To verify that some of the DXP enzymes when overex-
pressed were differentially soluble, each of the enzymes was
expressed individually in three distinct expression systems
in different strains of E. coli (BL21 strain - T7 promoter,M15 strain - T5 promoter and DH10B strain – araBAD
promoter) at two temperatures (37°C and 20°C). The stand-
ard dosage of inducers were used to trigger expression of
the proteins (10mM L-arabinose or 1mM IPTG [6,23]). In
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to 90%, Figure 2). The large variances in solubility across
proteins suggested that the method for identifying and
quantifying protein solubility is unbiased. This protein
solubility analysis method (similar to that used in [21])
was also further validated by filtration studies (Additional
file 1). A group of the DXP enzymes (DXS, ISPG, ISPH
and ISPA) were indeed found to be highly insoluble (solu-
bility less than 30% in all conditions examined) (Figure 2).
DXS (the committed enzyme of DXP pathway) was previ-
ously identified to be crucial (rate-limiting) for isopre-
noid production, was found to be highly insoluble in
the present study. Using dxs as a prototype of highly
insoluble enzymes, we next examined the impact of in-
clusion body formation on metabolic engineering of E.
coli for isoprenoid production.
Enzymatic activity of insoluble recombinant DXS
Although some inclusion bodies formed with certain
enzymes were reported to be active [24], it is generally
accepted that inclusion bodies contain primarily incorrect
folded proteins and are functionally inactive [25]. To test
whether insoluble DXS is catalytically functional, lysates
containing recombinant insoluble DXS was characterized
by an in vitro assay, where DXS activity was determined
by measuring the formation of DXP. It was found thatFigure 2 Solubility of DXP enzymes in E. coli. The expression systems a
soluble proteins. All the enzymes in the DXP pathway were individually exp
M15 strain - T5 promoter; C: DH10B strain - araBAD promoter) at two temp
and standard errors were drawn on the plot. The quantifications were base
strain – araBAD promoter, 20°C) were demonstrated in D. S: soluble protein
were cropped from individual gel images and aligned for demonstration p
those in 37°C in all systems (Figure 2A-C).DXP was produced at low levels (less than 1 μM) with in-
soluble DXS containing lysates. As a comparison, the
same amount of purified soluble DXS (Figure 3 B) was
spiked into the lysates, and high level of DXP (~700 μM)
was produced (Figure 3 A), confirming that specific activ-
ity of insoluble DXS was significantly lower than that of
soluble DXS. This observation suggested that strategies to
increase the solubility of DXS may confer higher activity
and metabolic flux for isoprenoid production in vivo.
Improving solubility of DXS enhanced the production
of DXP
Improvement of recombinant protein solubility has
been intensively studied for the purpose of overprodu-
cing soluble proteins, and various effective strategies
have been reported, such as lowering incubation tem-
perature [25], use of fusion partner [26], overexpression
of chaperone proteins [27] and protein mutagenesis
[28]. Recently, Prasad et al. reported a simple yet effect-
ive approach to increase the solubility of recombinant
proteins, where sorbitol at high concentration reduced
protein aggregation in E. coli [29]. To test if this ap-
proach could increase the solubility of DXS, high con-
centration of sorbitol was added directly to the cells in
culture. The solubility of DXS was examined and found
to be significantly increased (Figure 4 A and B). Othernd incubation temperatures played important roles in production of
ressed by three expression systems (A: BL21 strain - T7 promoter; B:
eratures (37°C and 20°C). Presented data were average of triplicates
d on image of SDS-PAGE gels, some of which (the set for DH10B
fraction; IS: insoluble protein fraction. The pictures of DXP proteins
urpose. The protein solubilities were generally higher in 20°C than
Figure 3 In vitro activity analysis of insoluble DXS. Activity of insoluble DXS was found to be much lower than that of equal amount of
soluble DXS by quantifying the quantity of DXP they produced in vitro. A: Quantification of the in vitro produced DXP by insoluble DXS, insoluble
DXS + purified DXS (soluble) and purified DXS (soluble), presented data were average of triplicates and standard errors were drawn on the plot;
B: Quantification of the insoluble DXS and the purified DXS (soluble) used in A, lane 1: the cell lysate containing insoluble DXS, lane 2: protein
markers, lane 3: purified soluble DXS, the arrowed band was DXS.
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fering agents (HEPES, phosphate) did not improve the
solubility of dxs significantly (Figure 4 A). In addition,
sorbitol similarly improved the solubility of some but
not all other DXP enzymes (Additional file 2).Figure 4 Addition of chemicals for increasing solubility of DXS and p
different properties were used to increase solubility of dxs. The expression
which produced the most soluble DXS were used here. The use of high co
DXS and production of DXP (product of DXS). A: Effects of the chemical ad
solubility by sorbitol, S: soluble fraction, IS: insoluble fraction; the arrowed b
addition of sorbitol increased DXP production in the cells expressing DXS b
Presented data were average of triplicates and standard errors were drawn
statistical analysis.To demonstrate that improved solubility of DXS results
in enhanced production of DXP (committed metabolic
intermediate in the DXP pathway), cells grown in sorbitol
were lysed and the extracts quantified by LC-MS. It was
found that concentrations of DXP were significantlyroduction of deoxyxylulose phosphate (DXP). Chemicals with
system (araBAD promoter-DH10B strain) and the temperature (20°C)
ncentration of sorbitol was found to significantly increase solubility of
ditions on solubility of DXS; B: Illustration of increased protein
and was DXS; C: Effects of sorbitol addition on production of DXP;
ut not in the ones expressing DXS (R398A), a nonfunctional mutant.
on the plot. Student’s t-test was used to calculate the p values in the
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(Figure 4 C). Addition of sorbitol did not alter the produc-
tion of DXP with cells overexpressing a nonfunctional
DXS (Figure 4 C, the construction and characterization of
the nonfunctional dxs was described in Additional file 3),
indicative that the effect of sorbitol on cells overexpressing
functional enzyme was likely be due to the increase in the
concentration of soluble DXS. A parallel increase in the
concentrations of MEP and MEC (Figure 1) were also
observed (Additional file 4), suggesting that sorbitol
increased the flux through the entire DXP pathway in cells
overexpressing DXS.
Improvement of ERG12 solubility and overproduction of
mevalonate phosphate
To extend the observation of the effect of sorbitol, a
critical enzyme (ERG12) in the mevalonate pathway
(the other isoprenoid precursor producing pathway,
Figure 5 A) was investigated. More than half of overex-
pressed ERG12 was insoluble and sorbitol was similarlyFigure 5 Addition of chemicals for increasing solubility of ERG12 and
concentration of sorbitol was also found to increase solubility of ERG12, a c
precursor production pathway), and production of MVAP (product of ERG1
pathway; MVA: Mevalonate, MVAP: Mevalonate phosphate, MVAPP: Mevalo
diphosphate; ERG12: mevalonate kinase, ERG8: mevalonate phosphate kina
addition on solubility of ERG12, S: soluble fraction, IS: insoluble fraction; C:
ERG19 were not present in E. coli and also not recombinantly expressed, M
activity of ERG12. Presented data were average of triplicates and standard e
the p values in the statistical analysis.found to enhance the solubility of this enzyme
(Figure 5 B). In line with the hypothesis that increased
solubility confers higher enzymatic activity and better
productivity of the respective metabolite, the produc-
tion of mevalonate phosphate (MVAP) was doubled
in the presence of high concentrations of sorbitol
(Figure 5 C). Since the MVA pathway is not endogen-
ous to E. coli (Figure 5 A), the production and accu-
mulation of MVAP was attributed to the enzymatic
activity of ERG12.
Discussion
This study addressed an important and often overlooked
issue of the solubility of over-expressed recombinant hom-
ologous or heterologous enzymes in metabolic engineering.
Specifically, we investigated the solubility status of overex-
pressed DXP enzymes and a heterologous enzyme of the
MVA pathway and the impacts on the production of crit-
ical precursor metabolites (DXP or MVAP), which are
building blocks of all the isoprenoids. It was unexpectedproduction of mevalonate phosphate (MVAP). The use of high
ritical enzyme in the mevalonate pathway (the other isoprenoid
2). A: Metabolites and enzymes related to the mevalonate (MVA)
nate diphosphate, IPP: Isopentenyl diphosphate, DMAPP: Dimethylallyl
se, ERG19: mevalonate diphosphate decarboxylase; B: Effects of sorbitol
Effects of sorbitol addition on production of MVAP; Since ERG8 and
VAP accumulated in ERG12 expressing E. coli , directly indicating
rrors were drawn on the plot. Student’s t-test was used to calculate
Zhou et al. Microbial Cell Factories 2012, 11:148 Page 6 of 8
http://www.microbialcellfactories.com/content/11/1/148that four out of nine enzymes in DXP pathway (DXS, ISPA,
ISPG and ISPH) were highly insoluble, despite being en-
dogenous enzymes. Overexpression of DXS resulted in the
accumulation of highly insoluble and non-functional (< 1%
activity of the equivalent soluble form) enzyme. This obser-
vation cautions against the assumption that overexpression
of an enzyme necessarily confers higher enzymatic activity.
Interestingly, the combinatorial screening study [9] based
on this contentious assumption identified three rate-
limiting DXP enzymes (IDI, ISPD and ISPF), which inci-
dentally were found to be highly soluble (Figure 2). It is
thus not unreasonable to speculate that the previously
thought to be ‘non rate-limiting’ enzymes found to be in-
soluble in this study, may serve to enhance the productions
of isoprenoids when expressed in soluble forms.
Using DXS as a model enzyme, four commonly used
fusion partners, trxA [31], nusA [18], slyD [32] and
malE [33] were fused at the N-terminus of DXS in the
attempt to increase solubility. The use of these fusion
partners did not significantly increase the solubility of
DXS (Additional file 5). The effectiveness of the fusion
partners in enhancing protein solubility is largely
protein-dependent and unpredictable [26,34]. Cysteine
residues on surface of DXS (C32, C330 and C457), may
form non-specific disulfide bonds and result in protein
aggregation [28]. Site-directed mutagenesis of these
residues also did not improve solubility (Additional file
6), suggesting that the aggregation of dxs protein was
not due to disulfide bond mediated interactions.
Osmolytes have been shown to improve overexpressed
proteins in E. coli [29]. Sorbitol at high concentrations sig-
nificantly improved DXS solubility and the production of
the metabolic product (DXP) in E. coli, indicating that
solubility of recombinant enzymes is an important factor
in the production of secondary metabolites. Consistent
with this suggestion was that ERG12, another model en-
zyme, also showed improved solubility and secondary me-
tabolite production in the presence of sorbitol. The reason
why the metabolic intermediates (DXP, MEP and MEC
etc.) instead of final product (lycopene etc.) were used as
read-out for characterization of DXS was that rate limiting
step (ISPG) existed between the intermediates and the
isoprenoid products (Zhou et al. PLoS One, In Press,
Additional file 7). It is worthy to note that the use of sorb-
itol is acceptable as a proof-of-concept but may not be
routinely used in microbial fermentation due simply to
the cost involved [29]. An alternative is to modify the host
microbes (such as manipulation of cellular protein folding
system [27,35]) to render these proteins more soluble for
industrial applications.
Conclusion
In this study, about half of the nine DXP proteins (DXS,
ISPG, ISPH and ISPA) were found to be highly insolublewhen overexpressed in E. coli. Insoluble DXS, the commit-
ted enzyme of the DXP pathway, showed significantly less
enzymatic activity when compared to the equivalent
amount of soluble enzyme in vitro. High concentration of
sorbitol successfully increased the solubility of DXS and
resulted in a parallel increase in the metabolic product
(DXP). The strategy also improved both solubility and sec-
ondary metabolite production of ERG12, a critical enzyme
in the mevalonate pathway. This study highlighted the im-
portance of protein solubility in metabolic engineering of
microbes for the overproduction of isoprenoids.
Methods
Bacteria strains and plasmids
Bacteria strains and plasmids used in this study were sum-
marized in Additional file 8. All the DXP genes were amp-
lified from E. coli genomic DNA and cloned into the
modified pBAD-B (Invitrogen), pET-11a (Stratagene) and
pQE30 (Qiagen) plasmids with 6xhis tag, SacI, XhoI re-
striction enzyme sites. Fusion partners (trxA, nusA, malE
and slyD) were amplified from E. coli genomic DNA and
cloned into pBAD-dxs with NcoI and SacI sites. Erg12
was amplified from S. cerevisiae genomic DNA and cloned
into the modified pBAD-B plasmid with 6xhis tag, SacI
and XhoI restriction enzyme sites. Dxs mutants R398A
[36], C32A, C330A, C457A and C32A-C330A-C457A
were generated according the ‘megaprimer’ protocol [37].
Primers used in this study were summarized in Additional
file 8. All the pET-11a, pBAD-B and pQE30 based plas-
mids were transformed into E. coli BL21-Gold (DE3), E.
coli DH10B and E. coli M15 respectively. pAC-LYC was
co-transformed with all the plasmids except pBAD-erg12.
E. coli growth and induction of protein expression
A colony was picked from agar plate, inoculated into
2xPY medium (20g/L Peptone, 10g/L Yeast extract, and
10g/L NaCl, pH=7) containing proper antibiotics, and
incubated overnight. Ten microliter aliquots of overnight
grown cell culture were inoculated into 1mL 2xPY
medium in 14mL Falcon tube. Cells were grown at 37°C/
300rpm till OD595 reached the range of 0.5~1.0. The cells
were then induced with 1mM IPTG (E. coli BL21-Gold
(DE3) and E. coli M15) or 10mM L-arabinose (E. coli
DH10B) and grown at 37°C or 20°C for indicated time be-
fore collected for protein solubility assay or metabolite
assay. Additives (sorbitol, betaine, phosphate, HEPES,
mevalonate etc.) were also fed to cell culture upon induc-
tion if necessary.
Prediction and quantification of protein solubility
The revised WH algorithm [18] was used for prediction of
protein solubility. Protein solubility was experimentally
quantified by centrifugation [21] as described below. At
24h after induction, cell suspension equivalent to 1mL
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resuspended in 100uL B-PERII reagent (Pierce). The mix-
tures were vortexed at room temperature for 10min, and
centrifuged at 16,000g for 10min. The supernatant con-
taining soluble cell lysates, and the pellets (resuspended
in 100uL 2% w/v SDS) containing insoluble cell lysates
were analyzed by SDS-PAGE. The SDS-PAGE gel was
visualized by staining with instant blue (Gentaur), and
image of the gel was processed and quantified by the
software Quantity One (Bio-Rad). Protein solubility was
defined as the quantity of the target protein in soluble
cell lysates over that in total cell lysates (soluble cell
lysates + insoluble cell lysates). Because ERG12 protein
cannot be separated from an abundant endogenous pro-
tein on SDS-PAGE, it was detected by western blot ana-
lysis with anti-6xhis tag antibody (Penta-his Ab, Qiagen).
In vitro quantification of dxs activity
The DH10B strain – araBAD promoter system was used
to produce DXS at 20°C, whose catalytic activity was char-
acterized in vitro. At 24h after induction, insoluble cell
lysates were prepared as described above except that they
were well resuspended in 100uL NPI-10 (50mM
NaH2PO4, 300mM NaCl, 10mM imidazole, pH=8) instead
of 2% w/v SDS. 1uL the mixture was then incubated in
20uL in vitro reaction solution containing 40mM Tris
(pH=6), 10mM pyruvate, 20mM DL-glyceraldehyde
3-phosphate, 1mM thiamine diphosphate, 12.5 mM MgCl2
and 5 mM β-mercaptoethanol. The reaction was termi-
nated by 1mL acidic extraction solution (acetonitrile/
methanol/water 40:40:20, 100mM formic acid) after 2h
incubation at 37°C, and formation of DXP was quantified
by SPE UPLC-MS.
SPE UPLC-MS quantification of DXP and MVAP
Concentration of DXP and MVAP in cell culture was
quantified by SPE UPLC-MS. At 5h after induction, 50uL
cell suspension was sampled and diluted in 1mL acidic ex-
traction solution (acetonitrile/methanol/water 40:40:20,
100mM formic acid) and centrifuged at 16,000g for 1min.
Supernatant was loaded to a cartridge holding 11 mg LC-
NH2 resin (Sigma) that was activated by 200uL acidic ex-
traction solution. The cartridge was centrifuged at 2,800g
for 1min, and eluted with 100uL 1% w/v NH4OH that
was subsequently neutralized by 0.75uL acetic acid. The
eluate was analyzed by UPLC (Waters ACQUITY UPLC)
– MS (Bruker micrOTOF II) as described below. Aqueous
solution (A) containing 15 mM acetic acid and 10mM
tributylamine and methanol (B) were used as mobile
phase with a UPLC C18 column (Waters CSH C18
1.7μm 2.1x 50mm). The elution was done at 0.15 mL/
min with gradient (start: 100% A, 1.8min: 100% A,
3.1min: 60% A, 4.9min: 60% A, 5.4min: 10% A, 9.5min:
10% A, 10min: 100% A). Electrospray ionization wasused and (TOF)MS was operated to scan 50–800 m/z in
negative mode with -500V end plate voltage and 4500V
capillary voltage. Nebulizer gas was provided in 1bar,
drying gas temperature was 9mL/min, and dry gas
temperature was 200°C. Sample injection volume was
5μL. A range of m/z was extracted from the acquired
data for DXP (213.0170±0.03, eluted at 5.6min) or
MVAP (227.0315±0.03, eluted at 6.7min). The integrated
area of signal peak at its retention time then was calcu-
lated for the metabolites with the software provided by
the manufacturer. Based on the integrated area of signal,
concentration of DXP and MVAP were determined by
interpolating from a standard dilution of the intermedi-
ates prepared in biological matrix.
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